The impact of interaction between verteporfin and yes-associated protein 1/transcriptional coactivator with PDZ-binding motif-TEA domain pathway on the progression of isocitrate dehydrogenase wild-type glioblastoma.

IF 2.6 Q2 CLINICAL NEUROLOGY Journal of Central Nervous System Disease Pub Date : 2023-01-01 DOI:10.1177/11795735231195760

Mahmoud Osama, Muhammed Amir Essibayi, Mona Osama, Ismail A Ibrahim, Mostafa Nasr Mostafa, Murat Şakir Ekşi

{"title":"The impact of interaction between verteporfin and yes-associated protein 1/transcriptional coactivator with PDZ-binding motif-TEA domain pathway on the progression of isocitrate dehydrogenase wild-type glioblastoma.","authors":"Mahmoud Osama, Muhammed Amir Essibayi, Mona Osama, Ismail A Ibrahim, Mostafa Nasr Mostafa, Murat Şakir Ekşi","doi":"10.1177/11795735231195760","DOIUrl":null,"url":null,"abstract":"<p><p>Verteporfin and 5-ALA are used for visualizing malignant tissue components in different body tumors and as photodynamic therapy in treating isocitrate dehydrogenase (IDH) wild-type glioblastoma (GBM). Additionally, verteporfin interferes with Yes-associated protein 1 (YAP)/Transcriptional coactivator with PDZ-binding motif - TEA domain (TAZ-TEAD) pathway, thus inhibiting the downstream effect of these oncogenes and reducing the malignant properties of GBM. Animal studies have shown verteporfin to be successful in increasing survival rates, which have led to the conduction of phase 1 and 2 clinical trials to further investigate its efficacy in treating GBM. In this article, we aimed to review the novel mechanism of verteporfin's action, the impact of its interaction with YAP/TAZ-TEAD, its effect on glioblastoma stem cells, and its role in inducing ferroptosis.</p>","PeriodicalId":15218,"journal":{"name":"Journal of Central Nervous System Disease","volume":null,"pages":null},"PeriodicalIF":2.6000,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/83/b7/10.1177_11795735231195760.PMC10439684.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Central Nervous System Disease","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1177/11795735231195760","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Verteporfin and 5-ALA are used for visualizing malignant tissue components in different body tumors and as photodynamic therapy in treating isocitrate dehydrogenase (IDH) wild-type glioblastoma (GBM). Additionally, verteporfin interferes with Yes-associated protein 1 (YAP)/Transcriptional coactivator with PDZ-binding motif - TEA domain (TAZ-TEAD) pathway, thus inhibiting the downstream effect of these oncogenes and reducing the malignant properties of GBM. Animal studies have shown verteporfin to be successful in increasing survival rates, which have led to the conduction of phase 1 and 2 clinical trials to further investigate its efficacy in treating GBM. In this article, we aimed to review the novel mechanism of verteporfin's action, the impact of its interaction with YAP/TAZ-TEAD, its effect on glioblastoma stem cells, and its role in inducing ferroptosis.

Abstract Image

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

维替泊芬与es相关蛋白1/转录共激活因子与pdz结合基序- tea区域通路相互作用对异柠檬酸脱氢酶野生型胶质母细胞瘤进展的影响。

维替泊芬和5-ALA用于观察不同身体肿瘤的恶性组织成分，并作为光动力疗法治疗异柠檬酸脱氢酶(IDH)野生型胶质母细胞瘤(GBM)。此外，维替波特芬干扰yes相关蛋白1 (YAP)/ pdz结合基序-TEA结构域转录共激活因子(TAZ-TEAD)通路，从而抑制这些癌基因的下游作用，降低GBM的恶性特性。动物研究表明，维替波特芬成功地提高了生存率，这导致了1期和2期临床试验的进行，以进一步研究其治疗GBM的疗效。在本文中，我们旨在综述维替泊芬作用的新机制，它与YAP/TAZ-TEAD相互作用的影响，它对胶质母细胞瘤干细胞的影响，以及它在诱导铁凋亡中的作用。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊